Carey Anders, MD
Medical Oncology · Chapel Hill, NCNPI 1073786893
Payments from drug & device makers
Across 334 payments — averaging $61,340 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$16.8M
- Seagen Inc.$2.8M
- Astrazeneca UK Limited$320K
- Merck$235K
- AstraZeneca$93K
- GSK$71K
- plus $183K from 19 others
Across 6 payments — averaging $1123.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$5K
- Pfizer$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 149 | $16,793,922 |
| Seagen Inc. | 63 | $2,791,500 |
| Astrazeneca UK Limited | 18 | $320,474 |
| Merck | 5 | $234,817 |
| AstraZeneca | 24 | $92,905 |
| GSK | 2 | $70,860 |
| Beone Medicines USA, Inc. | 5 | $38,117 |
| Ipsen Bioscience Inc. | 11 | $35,387 |
| Genentech, Inc. | 13 | $19,748 |
| Eli Lilly | 1 | $16,744 |
| Ipsen Biopharmaceuticals, Inc | 18 | $16,342 |
| Tesaro, Inc. | 2 | $11,644 |
| Hoffmann-la Roche Limited | 5 | $9,797 |
| Janssen Global Services, LLC | 1 | $6,500 |
| Beigene USA, Inc. | 2 | $5,617 |
| Eisai Inc. | 2 | $4,313 |
| Daiichi Sankyo Inc. | 3 | $3,862 |
| Sanofi | 1 | $3,645 |
| F. Hoffmann-la Roche AG | 2 | $3,040 |
| Janssen Research & Development, LLC | 1 | $2,400 |
| Immunomedics, Inc. | 1 | $2,000 |
| Athenex Pharmaceutical Division, LLC | 1 | $2,000 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,679 |
| Stemline Therapeutics Inc. | 2 | $72 |
| Gilead | 1 | $12 |
How this compares
$20,487,397 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chapel Hill
- Thomas StinchcombeChapel Hill$5.4M
- Elizabeth DeesChapel Hill$3.1M
- Shetal PatelChapel Hill$2.2M
- Natalie GroverChapel Hill$803K
- Marcie RichesChapel Hill$163K
- Stephen KimaniChapel Hill$72K
- John StricklerDurham$23.5M
- Antoinette TanCharlotte$14.9M
- Andrew ArmstrongDurham$8.6M
- Jeffrey ClarkeDurham$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.